S-23 and LGD-4033 both come up in the same conversations; they overlap on Bone. S-23: S-23 is a high-affinity, orally active selective androgen receptor modulator (SARM) first characterized as a candidate for hormonal male contraception. LGD-4033: LGD-4033, also known as ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator, a class of compounds abbreviated as SARM.
S-23 is a high-affinity, orally active selective androgen receptor modulator (SARM) first characterized as a candidate for hormonal male contraception. It binds the androgen receptor as a full agonist and, in animal studies, builds lean muscle mass and bone mineral density while cutting fat, a tissue-selective anabolic profile that has drawn strong interest for body recomposition. It also potently and reversibly suppresses testosterone and sperm production, which is central to both its contraceptive rationale and its cautions.
LGD-4033, also known as ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator, a class of compounds abbreviated as SARM. It binds the androgen receptor, the same target acted on by testosterone, but is designed to stimulate muscle and bone while having weaker effects on other tissues. First described by Ligand Pharmaceuticals and later developed by Viking Therapeutics, it has been studied for muscle wasting but is not approved for any medical use, and it is banned in sport and sold illicitly to bodybuilders.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
High-affinity selective agonist
Selective tissue-preferential agonist
Suppression
Reduction
Dose-dependent suppression of endogenous testosterone
Lowers HDL and SHBG dose-dependently
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.